S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
NASDAQ:SGTX

Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$22.09
$23.10
50-Day Range
$20.92
$23.06
52-Week Range
$3.77
$28.00
Volume
83,600 shs
Average Volume
62,902 shs
Market Capitalization
$56.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Sigilon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
6.5% Downside
$21.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($12.65) to ($13.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.00 out of 5 stars

Medical Sector

917th out of 918 stocks

Pharmaceutical Preparations Industry

401st out of 402 stocks

SGTX stock logo

About Sigilon Therapeutics Stock (NASDAQ:SGTX)

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

SGTX Stock News Headlines

MCRB Seres Therapeutics, Inc.
Beam Therapeutics Inc.
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Eli Lilly Concludes Acquisition Of Sigilon Therapeutics
Lilly Completes Acquisition of Sigilon Therapeutics
SGTX - Sigilon Therapeutics, Inc.
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Sigilon stock up 500% on Lilly acquisition news
Eli Lilly To Acquire Sigilon Therapeutics
Lilly to Acquire Sigilon Therapeutics
See More Headlines
Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SGTX
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
-6.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-43,560,000.00
Net Margins
-171.29%
Pretax Margin
-171.29%

Debt

Sales & Book Value

Annual Sales
$12.94 million
Book Value
$15.68 per share

Miscellaneous

Free Float
2,351,000
Market Cap
$56.40 million
Optionable
Not Optionable
Beta
4.12
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Rogerio Vivaldi Coelho M.B.A. (Age 59)
    M.D., MBA, Pres, CEO & Director
    Comp: $924.67k
  • Mr. Philip Ashton-Rickardt Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $614.08k
  • Dr. Robert S. Langer Jr. (Age 74)
    Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
  • Dr. Daniel G. Anderson Ph.D. (Age 53)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Omid Veiseh Ph.D.
    Co-Founder
  • Dr. José Oberholzer M.D.
    Co-Founder
  • Dr. Arturo Vegas Ph.D.
    Co-Founder
  • Mr. Josias Fantato De Pontes M.B.A. (Age 56)
    CFO, Principal Accounting Officer & Treasurer
  • Mr. Bernd Kullmann M.B.A.
    Sr. VP and Head of Operations & Project Management
  • Mr. Matthew P. Kowalsky J.D. (Age 50)
    Chief of Staff, Chief Legal and Admin. Officer & Sec.

SGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Sigilon Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares.
View SGTX analyst ratings
or view top-rated stocks.

What is Sigilon Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12 month target prices for Sigilon Therapeutics' shares. Their SGTX share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 6.5%.
View analysts price targets for SGTX
or view top-rated stocks among Wall Street analysts.

How were Sigilon Therapeutics' earnings last quarter?

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) released its earnings results on Wednesday, November, 10th. The company reported ($8.19) EPS for the quarter, topping analysts' consensus estimates of ($8.58) by $0.39. The business had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 83.07% and a negative net margin of 171.29%.

When did Sigilon Therapeutics' stock split?

Shares of Sigilon Therapeutics reverse split on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did Sigilon Therapeutics IPO?

Sigilon Therapeutics (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity served as the underwriters for the IPO.

This page (NASDAQ:SGTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners